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Elevated plasma levels of plasminogen activa-
tor inhibitor-1 (PAI-1) have been correlated
with cardiovascular diseases such as myocar-
dial infarction and venous thrombosis. PAI-1
has also been shown to play an important
role in tumor development, diabetes, and obe-
sitas. Monoclonal antibodies MA-8H9D4 and
MA-56A7C10, and their single-chain variable
fragments (scFv), exhibit PAI-1-neutralizing
properties. In this study, a rigid-body docking
approach is used to predict the binding geome-
try of two distinct conformations of PAI-1
(active and latent) in complex with these anti-
body fragments. Resulting models were initially
refined by using the dead-end elimination
algorithm. Different filtering criteria based on
the mutagenesis studies and structural con-
siderations were applied to select the final
models. These were refined by using the slow-
cooling torsion-angle dynamic annealing pro-
tocol. The docked structures reveal the res-
pective epitopes and paratopes and their
potential interactions. This study provides cru-
cial information that is necessary for the rational
development of low-molecular weight PAI-1
inhibitors.
INTRODUCTION
Plasminogen activator inhibitor-1 (PAI-1) is a specific
inhibitor of the serine proteinases urokinase plasminogen
activator (u-PA) and tissue plasminogen activator (t-PA)
being a regulator of fibrinolysis and of extracellular prote-
olysis in turnover of the extracellular matrix (Gils and
Declerck, 2004; Durand et al., 2004). PAI-1 is a flexible
glycoprotein member of the serpin superfamily (Huber
and Carrel, 1989). Serpins are composed of three b sheetsStructure 15, 1105–1116and nine a helices, which form a scaffold supporting a sol-
vent-exposed reactive center loop of 20 amino acids
(designated P16–P80, including the bait peptide bond
P1-P10). Up until now, three different conformations of
PAI-1 have been characterized: the active, latent, and
substrate conformations (Hekman and Loskutoff, 1985;
Mottonen et al., 1992; Declerck et al., 1992; Munch et al.,
1993; Sharp et al., 1999; Nar et al., 2000). PAI-1 in its active
form interferes with the fibrinolytic balance by blocking
t-PA activity. Hence, elevated plasma PAI-1 levels might
enhance cardiovascular problems (e.g., myocardial
infarction and deep vein thrombosis) (Schulman and
Wiman, 1996; Robbie et al., 1996; Alessi et al., 1997; Nordt
et al., 1998; Schafer et al., 2001; De Taeye et al., 2004a).
The latent form of PAI-1 (Figure 1A) was the first form
of which the three-dimensional structure was resolved
(Mottonen et al., 1992). Afterwards, the structures of
a cleaved substrate variant (Aertgeerts et al., 1995) of
PAI-1 (Figure 1B) and of stabilized active PAI-1
(Figure 1C) variants were determined (Sharp et al., 1999;
Nar et al., 2000). In the three-dimensional structure of
active PAI-1, the reactive site loop (including the bait
peptide bond P1-P10) is exposed and is accessible for
the target proteinases. b sheet A is the largest of the three
b sheets and is composed of five strands that span the
long axis of the protein. b sheets B and C are shorter
and are composed of six and four strands, respectively.
There are nine a helices, designated A–I. Relative to the
face of b sheet A, all of these helices, except for helix F,
lie on the backside of the protein in the view given in Fig-
ure 1. Upon latency conversion, the N-terminal end of the
reactive site loop from P16 to P3 is inserted into b sheet A,
forming the new b strand 4A (Figure 1A). The environment
of the reactive center loop changes from solvent-exposed
to mostly buried, making the reactive center (P1-P10)
inaccessible for the target proteinases. The crystal struc-
ture of a cleaved noninhibitory substrate variant of PAI-1
(Aertgeerts et al., 1995) (Figure 1B) revealed that the
N-terminal side of the reactive site loop (P16–P3) is
inserted in a similar way as in latent PAI-1. The C-terminal
site of the reactive site loop (P40–P80) is positioned in the
same way as in active PAI-1 and forms b strand s1C,, September 2007 ª2007 Elsevier Ltd All rights reserved 1105
Structure
Docking of Recombinant Antibody Fragments and PAI-1Figure 1. Structures of Distinct Forms of PAI-1
(A–C) The structure of PAI-1 in the (A) latent, (B) cleaved, and (C) active conformations. b sheet A is shown in green, a helix F is shown in yellow, and the
reactive site loop is shown in red. The reactive site residues R346 andM347 (P1-P10) are represented as blue and purple spheres, respectively. (A), (B),
and (C) are based on Nar et al., 2000, Aertgeerts et al., 1995, and Mottonen et al., 1992, respectively.a configuration that places P10 at the ‘‘top’’ of the
molecule.
Currently, various strategies are being pursued to iden-
tify a PAI-1 inhibitor with therapeutic applications (Gils and
Declerck, 2004). Molecules were developed that inhibit
PAI-1 synthesis (Vinogradsky et al., 1997; Pawlowska
et al., 2001), and many monoclonal antibodies (MAs)
with PAI-1-neutralizing properties have been raised
(Nielsen et al., 1986; MacGregor et al., 1990; Declerck
and Collen, 1990; Keijer et al., 1991; Debrock and
Declerck, 1997; Gils and Declerck, 2004). Numerous
low-molecular weight (LMW) PAI-1 inhibitors have been
constructed (Charlton et al., 1996, 1997; Bjorquist et al.,
1998; Folkes et al., 2001; Gils et al., 2002; Elokdah et al.,
2004). Of those, only the recently discovered LMW PAI-1
inhibitor PAI-039 (tiplaxtinin) (Elokdah et al., 2004) may
be a promising PAI-1-inhibiting compound. PAI-039 has
been examined in several animal models that have indi-
cated the putative value of PAI-1 inhibition for therapeutic
purposes (Elokdah et al., 2004; Lijnen et al., 2005; Crandall
et al., 2006; Smith et al., 2006).
All previously described LMW compounds have been
selected through high-throughput screening of libraries
of chemical compounds. For the rational design of LMW
compounds, MAs might be of potential interest (van
Giezen et al., 1997; Berry et al., 1998; Montes et al.,
2000; Rupin et al., 2001). However, this approach requires
detailed insight in the structural andmolecular interactions
that play a role in the antibody-antigen interaction.
The specificity of an antibody is defined by its six
complementarity-determining regions (CDRs), which are
formed by three hypervariable loops of the variable light-
chain (VL) domain (CDR L1–L3) and three of the variable
heavy-chain (VH) domain (CDR H1–H3). These six CDRs
appear as loops at one end of a b barrel (Chothia et al.,1106 Structure 15, 1105–1116, September 2007 ª2007 Elsevier1989; Al-Lazikani et al., 1997; Morea et al., 1998). In juxta-
position, they form the surface (paratope) that interacts
with the antigen, referred to as the antibody-binding site
or epitope. Through molecular cloning, an antibody frag-
ment (single-chain variable fragment, scFv) comprising
only the VL and VH domains of the MA, but retaining sim-
ilar properties, can be constructed.
In previous studies, two scFvs were constructed with
similar properties as the corresponding full-length anti-
body (i.e., scFv-8H9D4 and scFv-56A7C10) (Debrock
et al., 1997; Verbeke et al., 2004). A mutagenesis ap-
proach was used to reveal the paratopes (Verbeke et al.,
2003, 2004) and epitopes (Bijnens et al., 2001; Naessens
et al., 2003) of scFv-8H9D4 and scFv-56A7C10.
However, prior to the construction of a LMW compound
based on PAI-1-neutralizing scFvs, detailed information
on the structural interaction of these scFvs with PAI-1
is required. This would improve our knowledge of the
molecular basis of antigen recognition by scFv-8H9D4
and scFv-56A7C10, the mechanism of action of these
PAI-1-neutralizing antibodies, and their pharmacological
implications.
So far, attempts to get crystals of PAI-1 in complex with
a neutralizing antibody or antibody fragment have failed.
The difficulties involved in obtaining sufficiently pure pro-
tein is aggravated by the spontaneous conversion of
active PAI-1 (with a half-life of 1–2 hr at 37C) to a nonreac-
tive, stable form (latent form [Hekman and Loskutoff,
1988]), along with the unsuccessful crystallization screen-
ing experiments of these complexes. These complexes
are also too large for accurate determination by standard
NMR techniques. To circumvent these difficulties, new
algorithms for protein-protein docking are used as
an alternative to crystallography and NMR techniques.
These docking programs supplemented with molecularLtd All rights reserved
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Docking of Recombinant Antibody Fragments and PAI-1modeling allow for the generation of putative antibody-
antigen complex models. We have chosen the ClusPro
docking suite (Comeau et al., 2004), which has been suc-
cessful in the blind Critical Assessment of Prediction of
Interactions (CAPRI) experiment (http://capri.ebi.ac.uk;
[Janin et al., 2003]). These structure-prediction tools in-
volve a degree of uncertainty. However, recent interna-
tional blind prediction challenges in the 3–5 rounds of
CAPRI have produced high-quality prediction for multiple
protein-protein targets (Mandell et al., 2001; Camacho
and Gatchell, 2003; Dominguez et al., 2003; Fernandez-
Recio et al., 2003; Gray et al., 2003; Li et al., 2003; Ber-
chanski et al., 2004; Wang et al., 2005).
On the other hand, there are also tools for modeling an-
tibody structures as implemented in the Web Antibody
Modeling server (WAM server) (Whitelegg and Rees,
2000). There are essentially two approaches to model an-
tibodies, as used in the WAM server: knowledge-based
methods such as database searching, in which the clos-
est-matching database loop (either from antibodies, or
from the entire Brookhaven Protein Data Bank [Berman
et al., 2000]) in sequence and length is used as a model;
and ab initio methods, such as the CONGEN conforma-
tional search method (Bruccoleri and Karplus, 1987). The
most sequence-homologous known loops of the same ca-
nonical class are used to model canonical loops, minimiz-
ing to smooth joins. From all of the CDR loops, the H3 loop
is the most difficult to model (most CDR H3 loops are non-
canonical), as its conformation varies between structures
(Shirai et al., 1996, 1999). The CONGEN conformational
search in WAM (Martin et al., 1991; Pedersen et al.,
1992) gives better results in H3 modeling than other avail-
able methods. The most sequence-homologous frame-
works to the sequence being modeled are chosen from
a database of known antibody structures. The framework
of the light and heavy chains is chosen separately and fit
together by using certain conserved interface residues
on a mean b barrel of the known structures. Side chains
are resequenced in silico by using the maximum-overlap
method (Pedersen et al., 1992).
In this study, we present a structural characterization,
based on molecular modeling experiments, of the com-
plexes of two recombinant antibody fragments, scFv-
8H9D4 and scFv-56A7C10, with PAI-1. The current target
involves two challenges: (1) the structures of scFv-8H9D4
and scFv-56A7C10 are not known, and they must be pre-
dicted by homology modeling; (2) PAI-1 is a large and very
flexible protein. Incorporating biochemical information
available for scFv-8H9D4 and scFv-56A7C10 and PAI-1
can improve the level of confidence of the resulting
models. Binding interface data obtained from experi-
ments, particularly those obtained from single-site muta-
genesis studies, are commonly used in docking studies
(Webster et al., 1994; van Dijk et al., 2005). For a single-
site mutant, the change in binding affinity is measured af-
ter mutation at a particular residue. The loss of binding or
a significant decrease in binding affinity after mutation of
a residue suggests, in general, that this residue is located
at the binding interface.Structure 15, 1105–1116The potential therapeutic effectiveness of the inhibitory
antibodies used in this work has been demonstrated by
their high and specific affinity for PAI-1, forming an excel-
lent basis for the rational development of PAI-1-modulat-
ing agents. The affinity constants for the interaction of
scFv-8H9D4 and scFv-56A7C10 with active PAI-1 are
1.8 ± 0.7 3 109 M1 and 1.01 ± 0.3 3 109 M1, respec-
tively (Verbeke et al., 2004). The validity of the current
approach of monoclonal antibody-based rational drug
design is further corroborated by the observation that at-
tachment of small molecules to the epitope of MA-8H9D4
exerts the same effect as the antibody (De Taeye et al.,
2004b).
Eventually, in the current study, one final model was
selected for each of active PAI-1/scFv-8H9D4, latent
PAI-1/scFv-8H9D4, and active PAI-1/scFv-56A7C10.
The obtained structural details improve our knowledge
about the molecular basis of antigen recognition by
scFv-8H9D4 and scFv-56A7C10 and about the mecha-
nism of action of PAI-1-neutralizing antibodies. The inter-
actions between the two subunits of the models are ex-
tensively described, hereby providing detailed structural
information needed for the rational design of a LMW
PAI-1 inhibitor based on these scFvs.
RESULTS AND DISCUSSION
Complex PAI-1/scFv-8H9D4
The described filter and selection procedure yielded a final
model for the docking complex of scFv-8H9D4 with active
PAI-1 and one for the docking complex with latent PAI-1.
Themodel with active PAI-1 (Figure 2A) originates from the
DOT program, in which all CDR residues were defined as
an attraction list. The final selected model for the docking
complex with latent PAI-1 resulted from the ZDOCK pro-
gram and has the scFv-8H9D4 as a receptor (Figure 2B).
According to the study of protein-protein recognition
sites (Lo Conte et al., 1999), the antibody-antigen com-
plexes and protease-inhibitor complexes have an inter-
face area in the range of 1250–2000 A˚2. The overall range
of interface areas is wide (1150–4500 A˚2). However, most
values are clustered at the lower end of this interval. For
the PAI-1/scFv-8H9D4 models, the complex with latent
PAI-1 reveals a higher buried accessible surface area
(ASA) at the interface, compared to the complex with
active PAI-1 (1393 A˚2 and 1114 A˚2, respectively). Besides
a buried ASA that is closer to the reported average for
antibody-antigen complexes, the complex with latent
PAI-1 reveals a slightly better ratio of the buried ASA at
the interface to the entire buried ASA (8% versus 7% for
the active PAI-1 complex).
The gap volume index, describing the complementar-
ities of the interfaces, as calculated with SURFNET (Las-
kowski, 1995), resulted in a value of 2.0 A˚ for the complex
with active PAI-1 and 2.1 A˚ for the complexwith latent PAI-
1. Although these gap volume index values are relatively
low, they are not rare in antibody-antigen complexes
(Jones and Thornton, 1996)., September 2007 ª2007 Elsevier Ltd All rights reserved 1107
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Docking of Recombinant Antibody Fragments and PAI-1Figure 2. Cartoon Representation of the Docked Complexes
(A–C) Cartoon representation of the obtained complexes between (A) active PAI-1/scFv-8H9D4, (B) latent PAI-1/scFv-8H9D4, and (C) active PAI-1/
scFv-56A7C10. PAI-1 is shown in gray, and the scFvs are shown in pale yellow.The interface of the active PAI-1/scFv-8H9D4 complex
reveals a slightly more polar interface than the average
protein surface, as found in antibody-antigen interfaces.
A total of 52% of atoms at the interface are polar, produc-
ing a rather hydrophilic surface, which is in agreement with
the 51% reported mean value for antibody-antigen in-
terfaces (Lo Conte et al., 1999). The latent PAI-1/scFv-
8HD4 complex encloses a more hydrophilic interface,
with 54% of polar atoms in the interface.
In general, antibody-antigen interfaces contain an aver-
age of 9 (±5) hydrogen bonds (Laskowski, 1995). It has
been observed that not only side chain atoms, but also
main chain atoms, contribute to the interacting interface
area. Main chain contribution to interfaces cannot be ig-
nored, especially that of the carbonyl oxygen accounting
for 11% of the interface area, more than any other atom
(Lo Conte et al., 1999). As reported in the literature (Janin
et al., 1988), antibody-antigen interfaces are much richer
in aromatic residues (His, Tyr, Phe, Trp) and have a prefer-
ence for Tyr residues. On average, the latter contribute to
one-sixth of the interface. In the active PAI-1/scFv-8H9D4
complex, the Tyr residues count for one-fifth (22.5%) of
the buried ASA, while, for the latent PAI-1/scFv-8H9D4
complex, this values decreases to 16.4% (see Table 1
for the respective complexes).
In general, comparison of the free and complexed struc-
tures can show the changes that take place upon associ-
ation; however, this is not the case for complexes of pro-
teases, inhibitors, antigens, and antibodies that undergo
only small changes in conformation when forming com-
plexes with standard-size interfaces (Davies and Cohen,
1996) and including shifts in surface loops or movements
of short segments of the polypeptide chain of up to 1.5 A˚.
The root-mean-square (rms) deviation of the protein back-
bone between the active uncomplexed and complexed1108 Structure 15, 1105–1116, September 2007 ª2007 ElseviePAI-1 is 0.23 A˚. The rms deviation between the latent un-
complexed and complexed PAI-1molecules is 0.25 A˚. The
backbone rms deviation between the active and latent
PAI-1 structures comprising the residues experimentally
determined as being part of the scFv-8H9D4 epitope
amounts to 0.3 A˚. This low value is not surprising since,
as illustrated by the mutagenesis studies (Verbeke et al.,
2003), the complexes formed between scFv-8H9D4 and
either active PAI-1 or latent PAI-1 share an epitope region
(see Table 1) in an area in which the structural differences
between active and latent PAI-1 are not pronounced.
Although the complexes formed between scFv-8H9D4
and active or latent PAI-1 share, not surprisingly, the
same paratope and epitope regions (see Table 1), the
same residues are not always involved. The buried ASA
of the active PAI-1/scFv-8H9D4 model includes 25 and
31 residues of the paratope and epitope, respectively,
and the latent PAI-1/scFv-8H9D4 complex involves 31
and 38 residues of the paratope and epitope, respectively.
Even though only a minority of PAI-1 residues is common
to both complexes (E53, Q56, D297, R300, Q301, F302,
and Q303), it should be stressed that most of these have
been determined by mutagenesis studies to form a major
part of the epitope. The a-carbon rms difference between
the active and latent PAI-1 structures comprising the res-
idues experimentally determined as being part of the
scFv-8H9D4 epitope is significantly higher when a com-
plex is formed (2.8 A˚) than when no complexed is formed
(0.3 A˚).
The region of D297–D305 in PAI-1 largely contributes to
the buried ASA of the active and latent PAI-1/scFv-8H9D4
complexes (25% and 19%, respectively, of the buried
ASA). Some of these residues were found to be part of
the epitope: D297, R300, Q303, D305 (Naessens et al.,
2003). In the active PAI-1 complex, residue E53, alsor Ltd All rights reserved
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Docking of Recombinant Antibody Fragments and PAI-1Table 1. Residues at the Interface for the Docked Complexes
scFv Chain
Type
Residue
Paratope
Buried
ASA (A˚2)
% Buried
ASA Mutation
Residue
Epitope
Buried
ASA (A˚2)
% Buried
ASA Mutation
Active PAI-1/scFv-8H9D4
CDR1-VL Gln27 40.6 3.7 Gln47 1.0 0.1
Asp28 35.7 3.2 Gln48 12.5 1.1
Tyr30 124.4 11.3 Thr50 4.4 0.4
Tyr32 61.4 5.6 + Gly51 12.0 1.1
Tyr49 7.3 0.7 Gly52 47.2 4.2
CDR2-VL Arg50 65.2 6.0 Glu53 121.1 10.4 +
Arg53 64.0 5.8 Gln55 55.3 4.9
CDR3-VL Tyr91 25.3 2.3 + Gln56 70.0 6.2
Asp92 47.2 4.3 Gln59 18.7 1.7
Glu93 35.2 3.2 Lys65 91.3 8.1
Phe94 74.1 6.7 + Ile66 5.4 0.5
Phe96 4.0 0.4 + Asp67 41.8 3.7
Thr30 1.9 0.2 Asp68 36.9 3.2
CDR1-VH Asp31 62.6 5.7 Val106 36.9 3.2
Tyr32 25.8 2.3 Gln107 27.4 2.4
Asn33 18.4 1.7 Phe109 6.8 0.6
CDR2-VH Ile50 10.1 0.9 His112 7.7 0.7
His52 36.4 3.3 Asp297 3.6 0.3 +
Asn53 32.2 2.9 Arg300 41.5 3.7 +
Ser54 36.7 3.3 Gln301 19.0 1.7
Thr56 38.6 3.5 Phe302 97.3 8.6
Thr58 8.8 0.8 Gln303 75.9 6.7 +
CDR3-VH Lys96 38.4 3.5 Ala304 10.9 1.0
Leu97 132.2 12.0 + Asp305 28.0 2.5 +
Arg98 74.4 6.8 + Phe306 1.8 0.2
Thr307 71.3 6.3
Ser308 38.0 3.4
Ser310 3.8 0.3
Asp311 42.4 3.8
Glu313 95.9 8.5
Leu315 2.2 0.2
Latent PAI-1/scFv-8H9D4
Asp1 20.2 1.4 Arg18 39.1 2.9
CDR1-VL Gln27 33.2 2.3 Gln21 18.1 1.3
Tyr30 93.3 6.5 Gln22 36.0 2.6
Ser31 3.3 0.2 Gln25 64.0 4.7
Tyr32 69.2 4.8 + Ala26 63.4 4.7
CDR2-VL Arg50 62.8 4.4 Ser27 5.9 0.4
Arg53 19.0 1.3 Glu53 49.9 3.7 +
CDR3-VL Tyr91 21.8 1.5 + Gln56 4.6 0.3
(Continued on next page)Structure 15, 1105–1116, September 2007 ª2007 Elsevier Ltd All rights reserved 1109
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scFv Chain
Type
Residue
Paratope
Buried
ASA (A˚2)
% Buried
ASA Mutation
Residue
Epitope
Buried
ASA (A˚2)
% Buried
ASA Mutation
Asp92 47.1 3.3 Gln57 28.0 2.1
Glu93 72.2 5.0 Ala60 31.9 2.4
Phe94 87.4 6.1 + Ala61 11.9 0.9
Pro95 2.4 0.2 Asn252 29.4 2.2
Phe96 25.2 1.8 + Ile253 1.8 0.1
Ser28 22.3 1.6 Asp285 11.3 0.8
CDR1-VH Asp31 76.4 5.3 Arg287 61.5 4.5 +
Tyr32 30.8 2.1 Lys288 94.0 6.9
Asn33 32.5 2.3 Pro289 8.1 0.6
CDR2-VH Ile50 19.2 1.3 Glu291 28.4 2.1 +
His52 40.8 2.8 Asn292 97.8 7.2
Asn53 49.6 3.5 Leu293 45.3 3.3
Ser54 63.2 4.4 Gly294 34.4 2.5
Thr56 88.0 6.1 Thr296 60.6 4.5
Thr57 39.9 2.8 Asp297 4.7 0.3 +
Thr58 36.9 2.6 Phe299 21.0 1.5
Tyr59 21.9 1.5 Arg300 102.4 7.6 +
Gln61 63.7 4.4 Gln301 27.4 2.0
Lys64 56.0 3.9 Phe302 34.0 2.5
CDR3-VH Ser95 9.0 0.6 Gln303 62.9 4.6 +
Lys96 36.3 2.5 His316 7.6 0.6
Leu97 127.5 8.9 + Ala345 21.0 1.5
Arg98 59.6 4.2 + Arg346 15.2 1.1
Met347 76.3 5.6
Ala348 18.7 1.4
Pro349 46.9 3.5
Glu350 34.8 2.6
Glu351 1.5 0.1
Ile352 36.1 2.7
Met354 18.6 1.4
Active PAI-1/scFv-56A7C10
Asp1 38.3 3.2 Arg187 20 1.6
Ile2 16.7 1.4 His190 16.7 1.4
CDR1-VL Gln27 64.3 5.4 Tyr210 23.7 1.9
Asp28 19.6 1.6 Thr211 15.7 1.3
Ser30 34.3 2.7 Glu212 73.7 6.0
Ala32 12.8 1.1 Phe213 18.9 1.5
CDR2-VL Trp50 83.0 6.9 + Thr214 47.7 3.9
CDR3-VL His91 5.6 0.5 + Thr215 3.0 0.2
Tyr92 101.1 8.4 + Pro216 15.7 1.3
Asp93 72.7 6.1 + Asp217 12.5 1.0
Thr94 40.6 3.4 + Gly218 40.7 3.31110 Structure 15, 1105–1116, September 2007 ª2007 Elsevier Ltd All rights reserved
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scFv Chain
Type
Residue
Paratope
Buried
ASA (A˚2)
% Buried
ASA Mutation
Residue
Epitope
Buried
ASA (A˚2)
% Buried
ASA Mutation
Pro95 15.2 1.3 His219 22.5 1.8
Trp96 4.7 0.4 + Tyr220 103.3 8.4
Ser31 24.6 2.1 Asp222 3.5 0.3
CDR1-VH Val33 19.4 1.6 Tyr241 124.4 10.1
Trp47 2.4 0.2 Glu242 40.4 3.3 +
CDR2-VH Tyr50 14.7 1.2 Lys243 57.8 4.7 +
Asn52 1.6 0.1 Glu244 51.5 4.2 +
Tyr53 73.3 6.1 Gly264 3.1 0.2
Asn54 87.4 7.3 Asn265 77.0 6.3
Gly56 30.5 2.5 Met266 3.4 0.3
Thr57 25.6 2.1 Thr267 33.9 2.8
Lys58 83.7 7.0 Leu269 56.0 4.6
Tyr59 36.8 3.1 Pro270 12.0 1.0
Glu61 67.8 5.7 Arg271 23.8 1.9
Asn64 35.8 3.0 Met347 41.7 3.4
CDR3-VH Gly97 39.6 3.3 Pro349 94.2 7.7
Arg98 99.8 8.3 + Glu350 88.2 7.2 +
His99 45.8 3.8 + Glu351 57.6 4.7
Ile352 4.9 0.4
Ile353 26.8 2.2
Asp355 14.4 1.2 +
Residues, part of the epitope/paratope as determined with mutagenesis, are indicated with ‘‘+.’’identified as part of the epitope by mutagenesis, contrib-
utes most to the buried ASA (10% of the buried ASA
[Table 1]).
The polar interactions of both models (Table 2) confirm
the observation that the heavy-chain CDR3 has a great
impact on the antibody’s affinity and specificity. Mutation
of R98-VH (CDR3) in scFv-8H9D4 resulted in a total affinity
loss for PAI-1. The potential role of this residue is recon-
firmed in this docking study, revealing multiple interac-
tions of R98-VH (CDR3) with T307 andD311 of the epitope.
For the active PAI-1 complex, a salt bridge between
R98-VH (CDR3) and D311 of the epitope was present
(Figure 3A). The latter residue contributes 4% to the buried
ASA. However, this is not in agreement with experimental
evidence that the side chain of D311 has no specific role in
the epitope, since mutation of the PAI-1 residues D311-
N312-E313 into alanine residues resulted in a negligible
effect of the MA-8H9D4 affinity for PAI-1 (Naessens
et al., 2003). The interaction of R98-VH (CDR3) with T307
cannot be experimentally demonstrated by mutagenesis
of T307, since this interaction involves the backbone
C=O of T307 (Figure 3A). Having two predicted interac-
tions with S54-VH (CDR2) and T56-VH (CDR2), respec-
tively, residue Q303 appears to contribute significantly
to complex stabilization. Q303 contributes to 7% of theStructure 15, 1105–111buried ASA (Figure 3B). This confirms the role of Q303
as demonstrated by mutation into alanine, resulting in a
17-fold lower affinity for MA-8H9D4 (Naessens et al., 2003).
Also, in the latent PAI-1/scFv-8H9D4 complex, R98-VH
(CDR3) is a major interacting residue (Table 1) and hydro-
gen bonds to S27 of the PAI-1 latent structure. The crucial
role for the HCDR3 region in this model is further under-
lined by the interactions of K96-VH (CDR3) and L97-VH
(CDR3) with N292 and K288, respectively (Figure 3C).
The importance of L97-VH (CDR3) was also delineated
by mutagenesis studies. Regarding the CDR3 of the light
chain, Y91-VL (CDR3) interacts with R287. The functional
role of both residues was also emphasized by the muta-
genesis studies. Finally, both E53 and R300 interact with
residues of scFv-8H9D4 K64-VH (CDR2) and Y59-VH
(CDR2), in line with previous mutagenesis studies (Naes-
sens et al., 2003) pointing out E53 and R300 as important
residues (Figure 3D).
Complex PAI-1/scFv-56A7C10
No satisfying complexes could be generated with latent
PAI-1. The resulting models showed very little interaction
with the heavy chain of CDR3 and/or exhibited too few
polar interactions, like hydrogen bonds. The lack of any
reliable models with latent PAI-1 could be expected since6, September 2007 ª2007 Elsevier Ltd All rights reserved 1111
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Docking of Recombinant Antibody Fragments and PAI-1Table 2. Polar Interactions between the Paratope and
Epitope in the Docked Complexes
scFv Chain
Type
Residue
Paratope
Residue
Epitope
Distance
(A˚)
Active PAI-1/scFv-8H9D4 Complex
CDR1-VL Asp28 O Lys65 NZ 2.9
Tyr30 OH Asp68 N 3.0
Tyr30 OH Asp67 N 2.7
CDR2-VL Arg50 NH1 Ser308 O 3.0
Arg53 NH2 Gln107 O 2.6
CDR3-VL Asp92 OD1 Gln59 NE2 2.9
Asp92 OD2 Lys65 NZ 2.6
Asp92 O Gln59 NE2 3.3
Glu93 OE1 Lys 65 NZ 3.6
CDR2-VH His52 NE2 Phe302 O 2.6
Asn53 ND2 Pro301 O 3.3
Ser54 OG Gln303 OE1 2.6
Thr56 OG1 Gln303 NE2 3.1
CDR3-VH Arg98 NH2 Asp311 OD2 2.6
Arg98 NH2 Thr307 O 2.7
Arg98 NE Thr307 O 3.1
Latent PAI-1/scFv-8H9D4 Complex
CDR1-VL Gln27 NE2 Ala 345 O 3.3
CDR2-VL Arg50 NH2 Glu350 O 2.5
CDR3-VL Tyr91 O Arg287 NH1 2.8
Tyr91 O Arg287 NH2 2.8
Glu93 OE2 Gln301 N 3.0
CDR1-VH Asp140 O Gln22 NE2 3.2
Asn142 O Asn292 O 2.7
CDR2-VH Asn53 OD1 Arg18 NH1 2.7
Thr56 OG1 Gln57 O 3.5
Tyr59 O Arg300 NH1 2.5
Tyr59 O Arg300 NH2 2.8
Lys64 NZ Glu53 OE1 2.6
CDR3-VH Lys96 O Asn292 NDZ 2.9
Leu97 O Lys288 NZ 3.0
Arg98 NH2 Ser27 OG 2.8
Active PAI-1/scFv-56A7C10 Complex
CDR1-VL Gln27 NE2 Asn265 O 2.8
Asp28 O Asn265 ND2 3.2
CDR3-VL His91 NE2 Tyr220 OH 2.9
Tyr92 OH Asn265 ND2 3.3
Thr94 OG1 Arg271 NH2 2.8
Thr94 O Arg271 NH2 2.9
CDR2-VH Tyr53 OH Glu244 OE2 3.11112 Structure 15, 1105–1116, September 2007 ª2007 ElsevieMA-56A7C10 has a 25-fold lower affinity for latent PAI-1
compared to active PAI-1. This is the result of structural
changes in the epitope of MA-56A7C10 when the active
form converts to latent PAI-1. The backbone rms differ-
ence between the active and latent PAI-1 for the region
of the experimental residues of the scFv-56A7C10 epitope
rises to 5.8 A˚, a lot larger compared to the epitope of scFv-
8H9D4 (0.3 A˚).
The final selected model for the docked active PAI-1/
scFv-56A7C10 (Figure 2C) complex comes from the
ZDOCK program with scFv-56A7C10 as the ligand. This
complex has a buried ASA of 1213 A˚2, involving 29 resi-
dues of the paratope, a third of which are aromatic, and
32 residues of the epitope (Table 1). The ratio of the buried
ASA to the entire ASA is 11%, with a gap volume index
(Laskowski, 1995) of 1.2 A˚. The Tyr residues of the para-
tope at the complex interface contribute to one-sixth of
their area, as found in other antibody-antigen complexes
(Lo Conte et al., 1999). In this model, the rms deviation
of the protein backbone between the active uncomplexed
and complexed PAI-1 is 0.26 A˚. This complex shows 50%
of polar atoms in the interface.
Table 2 lists the interface residues of the resultingmodel
and their interactions. It has been stated (Verbeke et al.,
2004) that CDR3-VH was crucial for the paratope. In the
resulting model, there is a salt bridge between H99-VH
(CDR3) and E212 of the PAI-1 epitope. A hydrogen bond
interaction is present between R98-VH (CDR3) and D217
at the epitope. Also, polar interactions are predicted for
two paratope residues that were found to be important
in the mutagenesis study, H91-VL (CDR3) and Y92-VL
(CDR3), which interact with Y220 and N265, respectively
(Figure 3E). Although the role of T94-VL (CDR3) was doubt-
ful in the mutagenesis studies, in this model, this residue
shows a hydrogen bond with R271 of PAI-1. Residues
E242, K243, E244, E350, and D355, epitope residues
found by mutagenesis (Bijnens et al., 2001), also form
part of the epitope in this modeled complex (Tables 1
and 2). Particularly, K243 reveals a polar interaction with
N54-VH (CDR2) of the paratope (Figure 3F). Residues
at region Y241-E242-K243-E244 contribute about one-
fourth of the buried ASA.
In summary, recent developments and new protein-pro-
tein docking algorithms constitute an alternative to crys-
tallography. Usage of molecular modeling allows for the
generation of reliable antibody-antigen complexes. In
combination with other biochemical techniques, such as
site-directed mutagenesis, this approach may refine the
Table 2. Continued
scFv Chain
Type
Residue
Paratope
Residue
Epitope
Distance
(A˚)
Asn54 OD1 Lys243 NZ 2.5
Asn54 O Arg187 NH2 3.5
Lys58 NZ Tyr210 OH 3.2
CDR3-VH Arg98 NH2 Asp217 O 3.2
His99 NE2 Glu212 OE1 2.7r Ltd All rights reserved
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Docking of Recombinant Antibody Fragments and PAI-1current view of complex formation. With the aim of con-
structing a model system for the rational design of
a LMW compound with PAI-1-neutralizing properties, we
studied the structural interaction of scFv-8H9D4 and
scFv-56A7C10 with PAI-1. Molecular docking in conjunc-
tion with biochemical data from epitope and paratope
analysis as well as other filtering criteria resulted in three
complex models (i.e., scFv-8H9D4 with active and latent
PAI-1, scFv-56A7C10 with active PAI-1). Comparisons
of the interactions observed in the models with the data
frommutagenesis studies confirmed the reliability of these
models: mutation of some of the major interacting
residues in the complex models seriously affected the
antigen/scFv interaction.
Therefore, the outcome of this study is useful in identify-
ing compounds with comparable structure and biochem-
ical properties as the paratope of the respective scFvs.
Eventually, the rational design of such molecules could
result in a lead compound with a therapeutic application
in a variety of diseases. The biochemically guided com-
putational procedure may lead to information that is par-
ticularly useful for the rational design of a ligand with
Figure 3. Interactions at the Protein-Protein Interfaces
(A–F) Some interactions at the protein-protein interface for the
obtained complexes between (A and B) active PAI-1/scFv-8H9D4,
(C and D) latent PAI-1/scFv-8H9D4, and (E and F) active PAI-1/scFv-
56A7C10.Structure 15, 1105–1116enhanced affinity and for defining, in silico, sterical
aspects of protein-protein interactions.
EXPERIMENTAL PROCEDURES
Computer Modeling of the Antibody Fragments
Since there is no crystal structure of the monoclonal antibodies MA-
8H9D4 and MA-56A7C10, nor for their corresponding single-chain
variable fragments, the three-dimensional structural models of scFv-
8H9D4 and scFv-56A7C10 were built by using the online WAM-anti-
body-modeling (Whitelegg and Rees, 2000) server (http://antibody.
bath.ac.uk), which uses an updated version of the algorithm first imple-
mented in AbM (Oxford Molecular Ltd., Oxford, UK). The framework
was modeled by using homologous antibody templates. CDRs from
the light chain and CDR1 and CDR2 from the heavy chain were built
from homologous loops of the same canonical class. The noncanoni-
cal H-CDR3 was modeled by using a modified CAMALmethod (Martin
et al., 1989), which is based on a combined database/conformational
search approach. The linker chain between the two domains wasman-
ually inserted, since there is no available structure in the Protein Data
Bank for this moiety.
Three-Dimensional Structures of PAI-1 Variants
The three-dimensional structures of the PAI-1 variants were taken from
the Protein Data Bank: latent form (PDB code: 1LJ5); active form (PDB
code: 1DB2, Nar et al., 2000); and substrate form (PDB code: 9PAI,
Aertgeerts et al., 1995).
Docking Programs
The rigid-body docking approach of DOT (Ten Eyck et al., 1995; Man-
dell et al., 2001) and ZDOCK (Chen et al., 2003a, 2003b), implemented
in the ClusPRO algorithm (Comeau et al., 2004), was used to construct
models for scFv-8H9D4 and scFv-56A7C10 and each PAI-1 type.
ClusPro is the only docking technology that claims to find near-native
complex structures by using thermodynamics considerations
(Comeau et al., 2005).
Docking Simulations
For the ZDOCK program, four different settings with PAI-1 (active or la-
tent) or the antibody molecule as receptor or ligand, respectively, were
tested. With the DOT approach, ten different settings were established
to generate the docking models. In the cases in which the scFv was
used as the ligand, three approaches were used: (1) no attraction res-
idues were considered in the ligand; (2) attraction residues were
defined as the residues that constitute the paratope, as found bymuta-
genesis studies; (3) thewholeCDR loops, as defined byKABAT (except
for HCDR2, whichwas defined as in Chothia et al. [1989]), were defined
as the attraction residues. In the cases in which PAI-1 (latent or active)
was used as the ligand, either no attraction residues were considered,
or a set of attraction residues, comprising the epitope of the respective
scFv, as found by mutagenesis studies (Bijnens et al., 2001; Naessens
et al., 2003), wad defined. In general, all CDR loops, except HCDR3,
can be assigned to canonical classes that depend on the identity of
key residues in the antibody sequence (Chothia et al., 1989; Al-Lazikani
et al., 1997). Comparative analysis of the main chain CDR conforma-
tions in high-resolution antibody crystal structures revealed that 71
out of 79 CDR loops had a crystal structure conformation very close
to the standard conformation of the respective canonical classes (Al-
Lazikani et al., 1997).Besides theproblemof obtaining crystals, the var-
iations in the packing of the molecules in the crystal structure at the
light-heavy chain interface can also introduce alterations in the position
of the H3 loop with respect to the real orientation upon binding in solu-
tion. However, as mentioned in the Introduction, the method used in
WAM involves a conformational search, which gives better results in
H3 modeling than other available methods.
Based on the results of previous mutagenesis studies (Bijnens et al.,
2001; Naessens et al., 2003; Verbeke et al., 2003, 2004), both the, September 2007 ª2007 Elsevier Ltd All rights reserved 1113
Structure
Docking of Recombinant Antibody Fragments and PAI-1paratope and epitope of the PAI-1/scFv-8H9D4 and PAI-1/scFv-
56A7C10 complex could be implemented as a series of ‘‘attraction
lists’’: epitope of MA-8H9D4: E53, R287, E291, D297, R300, Q303,
and D305; paratope of scFv-8H9D4: S95, L97, and R98 (HCDR3);
Y32 (LCDR1); Y91, F94, and F96 (LCDR3); epitope of MA-56A7C10:
E242, K243, E244, E350, D355, and R356; paratope of scFv-
56A7C10: Y32 and V33 (HCDR1); L96, R98, H99, W100, and F100a
(HCDR3); W50 (LCDR2); H91, Y92, D93, T94, and W96 (LCDR3).
Each program (DOT or ZDOCK) generated 2000 energetically favor-
able structures per case; these structures were then clustered on the
basis of a pairwise root-mean-square (rms) deviation criterion (9 A˚
clustering radius), filtered (including side chain energy minimization),
and ranked by the ClusPro server (Camacho et al., 2000; Comeau
et al., 2004). These structures were CHARMm minimized (Brooks
et al., 1983) in the presence of the receptor and concatenated into
PDB NMR-formatted files.
Themodels, as obtained fromClusPro, were refined to geometrically
optimize the side chains, by using the dead-end elimination algorithm
(Desmet et al., 1992) implemented in BRUGEL (Delhaise et al., 1998).
These docked models were then ranked, per case, according to
some biochemical filters (see below) and, subsequently, according to
the buried accessible surface area (buried ASA) and electrostatic ener-
gies by using the BRUGEL program. The mean buried ASA was deter-
mined by using the Lee & Richards algorithm (Lee and Richards, 1971).
Filtering Criteria for the Docking Simulation of scFv-8H9D4
and scFv-56A7C10 with PAI-1
The following biochemical criteria were introduced for structural selec-
tion. First, a complex of an antibody with a large antigen usually in-
volves the six CDRs (Webster et al., 1994); consequently, only those
complexes involving three or more CDRs were considered. Second,
CDR3s, especially HCDR3, are known to play important roles in the an-
tigen interaction; therefore, complexes involving only HCDR3 and/or
LCDR3 were also retained. Third, previous mutagenesis studies high-
lighted the critical role of several epitope and paratope residues;
hence, complexes were also selected when at least one of those res-
idues was in contact with the antigen/antibody. Models that passed
through the biochemical filter were then ranked, per case, according
to the buried ASA by using the BRUGELmolecular simulation package
(Delhaise et al., 1998), which has been applied in different studies (Des-
met et al., 2005; Staelens et al., 2006a, 2006b). Per case, based on the
buried ASA, the three-dimensionally docked models from the sorted
list of the 30 highest-rankedmodels were inspected visually with BRU-
GEL. A series of about tenmodels, per case, passed this visual inspec-
tion; thus, no unrealistic models with main chain or side chain clashes
in the obtained docked complexes were selected. The models were
then clustered, by using the CHIMERA program (Pettersen et al.,
2004), according to the rms deviations between the backbone atoms
to find similar populations of docked complexes. From these clusters,
per case, the structures with the lowest rms deviation of the superim-
position were selected as representative for the cluster, then the
docked complex with the highest buried ASA was selected as our final
model per case. These models were further refined by using the slow-
cooling torsion-angle dynamic annealing protocol implemented in the
CNS program, Version 1.1 (Bru¨nger et al., 1998). This procedure allows
for the movement of the protein backbones as well as the side chains
during refinement. The protocol used was slow-cooling torsion-
angle dynamic annealing; a starting temperature of 1000 K with
a drop in temperature per cycle of dynamics (cool rate) of 25 K and
a molecular dynamic time step of 0.0005 ps were used. The quality
of the obtainedmodels was confirmed by evaluation of the Ramachan-
dran plots generated by PROCHECK (data not shown) (Laskowski
et al., 1993).
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